Arcutis Biotherapeutics Inc (ARQT, Financial) is set to release its Q3 2024 earnings on Nov 6, 2024. The consensus estimate for Q3 2024 revenue is $37.62 million, and the earnings are expected to come in at -$0.43 per share. The full year 2024's revenue is expected to be $166.27 million and the earnings are expected to be -$1.58 per share. More detailed estimate data can be found on the Forecast page.
Arcutis Biotherapeutics Inc (ARQT, Financial) Estimates Trends
Over the past 90 days, revenue estimates for Arcutis Biotherapeutics Inc (ARQT) for the full year 2024 have increased from $164.39 million to $166.27 million. However, estimates for 2025 have declined from $253.35 million to $248.50 million. Earnings estimates for the full year 2024 have improved from -$1.70 per share to -$1.58 per share, and for 2025, estimates have risen from -$1.19 per share to -$1.13 per share.
Arcutis Biotherapeutics Inc (ARQT, Financial) Reported History
In the previous quarter of June 30, 2024, Arcutis Biotherapeutics Inc's (ARQT) actual revenue was $30.86 million, which beat analysts' revenue expectations of $29.08 million by 6.11%. Arcutis Biotherapeutics Inc's (ARQT) actual earnings were -$0.42 per share, which beat analysts' earnings expectations of -$0.513 per share by 18.13%. After releasing the results, Arcutis Biotherapeutics Inc (ARQT) was down by -11.27% in one day.
Arcutis Biotherapeutics Inc (ARQT, Financial) 12 Month Price Targets
Based on the one-year price targets offered by 7 analysts, the average target price for Arcutis Biotherapeutics Inc (ARQT) is $18.57 with a high estimate of $27 and a low estimate of $12. The average target implies an upside of 112.98% from the current price of $8.72.
Based on GuruFocus estimates, the estimated GF Value for Arcutis Biotherapeutics Inc (ARQT, Financial) in one year is $0, suggesting a downside of -100% from the current price of $8.72.
Based on the consensus recommendation from 7 brokerage firms, Arcutis Biotherapeutics Inc's (ARQT, Financial) average brokerage recommendation is currently 1.9, indicating an "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
